Welcome to our dedicated page for Inuvo SEC filings (Ticker: INUV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Inuvo's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Inuvo's regulatory disclosures and financial reporting.
Inuvo, Inc. filed a current report describing a shareholder update call held on January 28, 2026. During this call, Robert C. Buchner, who becomes the company’s new Chief Executive Officer effective February 1, 2026, outlined his strategic priorities and vision for Inuvo’s next phase of growth.
The prepared remarks from this shareholder update are provided in a call script, which is included as an exhibit to the report and incorporated by reference for informational purposes. The company notes that this shareholder update material is being furnished under Regulation FD rather than formally filed under securities laws.
Inuvo, Inc. reported several corporate updates. Its Vertro subsidiary signed an amendment with Google LLC extending an existing Google Services Agreement by one month, moving the expiration date to February 28, 2026.
The company announced a leadership transition. Chief Operating Officer and director Robert C. Buchner becomes Chief Executive Officer on February 1, 2026 and Chairman of the Board immediately, while current CEO Richard K. Howe steps down from the CEO role on January 31, 2026 but remains on the Board. Inuvo entered into an amended and restated employment agreement with Mr. Buchner providing a minimum annual base salary of $400,000 and defining incentive eligibility and termination benefits.
In connection with the transition, Inuvo and Mr. Howe agreed to a separation package that includes separation pay totaling $682,813 over 22 months, payment for up to 18 months of COBRA continuation coverage, and full vesting of 120,001 restricted stock units on his termination date. Inuvo also furnished a press release with preliminary Q4 2025 revenue and a separate release announcing Mr. Buchner’s appointment.
Inuvo, Inc. entered into a securities purchase agreement to issue subordinated convertible notes with an aggregate principal amount of $3,333,333.33, issued with a 10% original issue discount and convertible into common stock at $3.10 per share under specified conditions. The company also signed a registration rights agreement requiring it to file and seek effectiveness of a resale registration statement for the related securities within set 30- and 60-day timelines. Under NYSE American rules, Inuvo may not issue more than 2,941,274 shares of common stock, equal to 19.99% of shares outstanding immediately before the agreement, without prior stockholder approval, and individual buyers are limited to 4.99% beneficial ownership, which they may increase to 9.99% with 61 days’ notice. Curvature Securities LLC acts as placement agent, receiving a 6% cash fee on gross proceeds from each drawdown plus $7,500 of expenses, and the new notes are subordinated to existing debt under a debt subordination agreement with the senior lender.
Inuvo, Inc. director Kenneth Ewell Lee reported the conversion of restricted stock units into common shares. On 01/08/2026, 3,000 restricted stock units were converted into 3,000 shares of Inuvo common stock at a price of $0.0000 per share through a transaction coded "M". After this transaction, Lee directly beneficially owned 54,500 shares of Inuvo common stock.
The filing notes that the share amounts were adjusted to reflect a 1-for-10 reverse stock split that occurred on June 10, 2025, and that each restricted stock unit represents a contingent right to receive one share of Inuvo common stock.
Inuvo, Inc. director Gordon J. Cameron reported a stock-based compensation transaction. On January 8, 2026, 3,000 restricted stock units were converted into 3,000 shares of Inuvo common stock at an exercise price of $0.0000, reflecting the vesting and settlement of equity awards rather than an open-market purchase. Following this transaction, Cameron beneficially owns 57,910 shares of Inuvo common stock directly and an additional 663 shares indirectly through his spouse. The reported share amounts have been adjusted to reflect a 1-for-10 reverse stock split that occurred on June 10, 2025.
Inuvo, Inc. reported that Chief Operating Officer and director Robert C. Buchner acquired common stock through the settlement of equity awards. On January 8, 2026, 3,000 restricted stock units were converted into 3,000 shares of common stock at an exercise price of $0.0000 per share. Following this transaction, Buchner directly holds 3,000 shares of Inuvo common stock. The number of restricted stock units and underlying shares reflects a 1-for-10 reverse stock split that occurred on June 10, 2025.
Inuvo, Inc. director Jonathan Bond reported the conversion of 3,000 restricted stock units into 3,000 shares of common stock on January 8, 2026. The Form 4 shows this as a code "M" transaction at a price of $0.0000 per share, indicating an exercise of equity awards rather than an open-market purchase.
After this transaction, Bond directly owns 12,000 shares of Inuvo common stock. The filing notes that the figures have been adjusted for a 1-for-10 reverse stock split that occurred on June 10, 2025. The derivative position in these restricted stock units is now reported as 0, reflecting that all 3,000 units referenced here have been converted into common shares.
Inuvo, Inc. director Kenneth Ewell Lee reported a new equity award. On 01/02/2026, he received 3,000 restricted stock units, each representing a contingent right to receive one share of Inuvo common stock. The units are listed as a derivative security with a conversion price of $0.0000 and are exercisable beginning 01/04/2027, with an expiration date of 01/04/2027. Following this transaction, he beneficially owns 3,000 derivative securities directly.
Inuvo, Inc. reported that one of its directors acquired equity-based compensation in the form of derivative securities. On 01/02/2026, the director received 3,000 restricted stock units, each representing a contingent right to receive one share of Inuvo common stock. The restricted stock units were acquired at a price of $0.0000 per unit and are listed as directly owned derivative securities. Following this grant, the director beneficially owns 3,000 derivative securities tied to Inuvo common stock, with the units shown as exercisable and expiring on 01/04/2027.
Inuvo, Inc. director Jonathan Bond reported receiving a grant of 3,000 restricted stock units of the company’s common stock. The Form 4 shows the RSU transaction date as 01/02/2026, with the units listed as directly owned. Each restricted stock unit represents a contingent right to receive one share of Inuvo common stock, and the RSUs have a date exercisable and expiration date of 01/04/2027. The transaction is reported as an acquisition of derivative securities at a stated price of $0.0000 per RSU.